In a report released today, Do Kim from BMO Capital maintained a Buy rating on TCR2 Therapeutics (TCRR), with a price target of $56.00. The company’s shares closed last Friday at $22.02.
According to TipRanks.com, Kim is a 5-star analyst with an average return of 24.3% and a 57.6% success rate. Kim covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Checkmate Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on TCR2 Therapeutics is a Strong Buy with an average price target of $48.33, which is an 119.5% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target.
See today’s analyst top recommended stocks >>
Based on TCR2 Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.45 million. In comparison, last year the company had a GAAP net loss of $12.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
